X4 Pharmaceuticals appoints Kelly Gold to Board of Directors

X4 Pharmaceuticals, Inc

Kelly Gold appointed as Class II director effective July 1, 2026; board expands from 5 to 6 members.
Gold is CFO of CAMP4 Therapeutics (Nasdaq: CAMP) and will serve on Audit Committee.
Gold brings financial leadership, capital markets expertise, and rare disease experience from Biogen.
No arrangements or family relationships with other directors/officers; standard compensation per non-employee director policy.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kelly Gold

Class II director

XFOR · X4 Pharmaceuticals, Inc

Effective: 2026-07-01
Filed: July 1, 2026, 4:13 PM ET

On June 30, 2026, of X4 Pharmaceuticals, Inc. (the “Company”) appointed Kelly Gold as a Class II director of the Company, effective as of July 1, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kelly Gold was appointed as Class II director at X4 Pharmaceuticals, Inc.

Action: appointed
Role: Class II director

Exact text from the filing

On June 30, 2026, of X4 Pharmaceuticals, Inc. (the “Company”) appointed Kelly Gold as a Class II director of the Company, effective as of July 1, 2026.

View on SEC.gov

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001501697-26-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.